ArticleEBioMedicine2019

Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).

Benedict J Panizza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.